Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Title:Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Volume: 11 Issue: 3

Author(s): Jinzheng Wang, Xiaoan Wen, Jun Liu and Hongbin Sun

Affiliation:

Keywords: Cancer, energy metabolism, inhibitors, mitochondrial biogenesis, PGC-1α, tumor migration.

Abstract: Recent studies show that enhanced mitochondrial biogenesis can “fuel” the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.

Cite this article as:

Wang Jinzheng, Wen Xiaoan, Liu Jun and Sun Hongbin, Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (3) . https://dx.doi.org/10.2174/1574892811666160418123628